Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris

• Status: Completed
• Trial end date: 2013-05-05
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Dapsone

Criteria

Inclusion Criteria:

• Diagnosis of acne vulgaris

• Willing to avoid excessive or prolonged exposure to ultraviolet light (e.g., sunlight, tanning beds) throughout the study

• If male, the subject must agree to shave the facial treatment area and agree to maintain his routine shaving regimen for the duration of the study

• willing to avoid applying moisturizers, sunscreens, cosmetics (except eye and lip makeup), and chemical peels throughout the study

Exclusion Criteria:

• Oral acne treatments within 6 months